Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
暂无分享,去创建一个
Michael Heuser | Brigitte Schlegelberger | Arnold Ganser | Wolf-Karsten Hofmann | M. Heuser | F. Thol | A. Ganser | W. Hofmann | M. Wlodarski | C. Niemeyer | M. Morgan | J. Krauter | O. Ottmann | B. Schlegelberger | G. Göhring | Jürgen Krauter | Michael Morgan | Felicitas Thol | Gudrun Göhring | Oliver Ottmann | Charlotte M Niemeyer | Marcin W Wlodarski | Kerstin Görlich | Martin Wichmann | G. Bug | Sofia Kade | Carola Schlarmann | Patrick Löffeld | Britta Kölking | Gesine Bug | M. Wichmann | B. Kölking | S. Kade | P. Löffeld | Carola Schlarmann | K. Görlich | K. Görlich | Britta Kölking | Sofia Kade | Patrick Löffeld | Kerstin Görlich
[1] A. Ganser,et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor , 1999, Annals of Hematology.
[2] G. Garcia-Manero,et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.
[3] K. Wagner,et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[5] Benjamin L Ebert,et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Verena I Gaidzik,et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Kaneko,et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.
[8] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[9] Torsten Haferlach,et al. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .
[11] H. Heimpel,et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.
[12] Li Ding,et al. RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.
[13] Xiang-Dong Fu,et al. Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis , 2007, Molecular and Cellular Biology.
[14] C. Schumann,et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Ganser,et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Porter. Oral iron chelators: Prospects for future development , 1989, European journal of haematology.
[17] D.,et al. Regression Models and Life-Tables , 2022 .
[18] K. Döhner,et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Staněk,et al. Where splicing joins chromatin , 2011, Nucleus.
[20] A. Jauch,et al. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group , 2009, Journal of cellular and molecular medicine.
[21] M. Jädersten,et al. Myelodysplastic syndromes: biology and treatment , 2009, Journal of internal medicine.
[22] E. Korn. Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.
[23] M. Heuser,et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications , 2012, Leukemia.
[24] Michael Heuser,et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2010, Blood.
[25] R. Arceci,et al. Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia , 2011 .
[26] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[27] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[28] K. Wagner,et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes , 2011, Haematologica.
[29] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.